Literature DB >> 1349647

Alpha adrenoceptor subtypes involved in the emetic action in dogs.

Y Hikasa1, S Ogasawara, K Takase.   

Abstract

In order to assess the involvement of alpha-1 and alpha-2 adrenoceptors in emesis, the emetic effect of eight alpha agonists was studied in dogs. The i.m. administration of each agonist elicited dose-dependent emesis. The order of potency in inducing emesis was: clonidine greater than oxymetazoline greater than tramazoline greater than naphazoline greater than xylazine greater than epinephrine greater than methoxamine = phenylephrine. The clonidine-induced emesis was antagonized by adrenoceptor antagonists showing alpha-2 blocking activity, yohimbine, tolazoline and phentolamine. Among these antagonists, yohimbine was the most effective. The alpha-1 and beta adrenergic, cholinergic, dopaminergic, histaminergic, serotonergic and opioid receptor antagonists did not prevent the clonidine-induced emesis. The emesis induced by oxymetazoline, tramazoline, xylazine, naphazoline and epinephrine was also antagonized by a selective alpha-2 adrenoceptor antagonist, yohimbine, but not by a selective alpha-1 adrenoceptor antagonist, prazosin. In contrast, methoxamine and phenylephrine-induced emesis was antagonized by prazosin, but not by yohimbine. Neither yohimbine nor prazosin prevented the morphine- and histamine-induced emesis. These results indicate that alpha-2 adrenoceptors are involved in the mediation of emetic action, and that the alpha adrenoceptor-mediated emesis does not involve beta adrenergic, cholinergic, dopaminergic, histaminergic, serotonergic and opioid receptors in the emetic pathway. This study further suggests that alpha adrenoceptors involved in the emesis are mainly of the alpha-2 type, although the involvement of alpha-1 adrenoceptors cannot be ruled out.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1349647

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Identifying mechanism-of-action targets for drugs and probes.

Authors:  Elisabet Gregori-Puigjané; Vincent Setola; Jérôme Hert; Brenda A Crews; John J Irwin; Eugen Lounkine; Lawrence Marnett; Bryan L Roth; Brian K Shoichet
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-18       Impact factor: 11.205

2.  Neurohormonal and metabolic effects of medetomidine compared with xylazine in healthy cats.

Authors:  Teppei Kanda; Yoshiaki Hikasa
Journal:  Can J Vet Res       Date:  2008-04       Impact factor: 1.310

3.  The effects of intravenous alfaxalone with and without premedication on intraocular pressure in healthy dogs.

Authors:  Bianca S Bauer; Barbara Ambros
Journal:  Can J Vet Res       Date:  2016-04       Impact factor: 1.310

4.  Neurohormonal and metabolic effects of medetomidine compared with xylazine in beagle dogs.

Authors:  T D Ambrisko; Y Hikasa
Journal:  Can J Vet Res       Date:  2002-01       Impact factor: 1.310

Review 5.  Pathophysiological and neurochemical mechanisms of postoperative nausea and vomiting.

Authors:  Charles C Horn; William J Wallisch; Gregg E Homanics; John P Williams
Journal:  Eur J Pharmacol       Date:  2013-10-26       Impact factor: 4.432

6.  Light-intensity Activity-related Nausea: An Unusual Presentation of Pheochromocytoma.

Authors:  Sakditad Saowapa; Parin Rattananon; Chutintorn Sriphrapradang
Journal:  Cureus       Date:  2019-10-17

Review 7.  Postoperative nausea and vomiting.

Authors:  Young Eun Moon
Journal:  Korean J Anesthesiol       Date:  2014-09-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.